undamentalytics Newsletter

Valamehr Bahram: insider trades

Chief executive, Officer at Fate Therapeutics Inc. No open-market purchases and 11 sales not made under a pre-set plan, reported from October 16, 2019 to August 5, 2026.

What happened after Valamehr Bahram’s sales?

After their sales, the shares moved +56.0% against the index over 12 months on average (a negative figure means selling was the right call); 67% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Valamehr Bahram: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 6 +9.5% −3.4% 67% 5 0.71 0.52 No reliable evidence
Sales, 12 months after the report 6 +56.0% −58.3% 67% 5 0.85 0.44 No reliable evidence
Sales, 12 months after the trade 6 +56.7% −58.1% 67% 5 0.85 0.44 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Fate Therapeutics Inc FATE President and CEO011October 16, 2019August 5, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
August 5, 2026August 4, 2026 FATE Sale $108,110 not yetnot yetnot yet
May 21, 2026May 20, 2026 FATE Sale $54,418 not yetnot yetnot yet
August 5, 2025August 4, 2025 FATE Sale $15,334 not yetnot yetnot yet
January 13, 2025January 10, 2025 FATE Sale $13,406 not yetnot yetnot yet
January 10, 2024January 9, 2024 FATE Sale $49,367 not yetnot yetnot yet
January 11, 2023January 10, 2023 FATE Sale $57,205 −1.7%−44.5%−42.8%
January 13, 2022January 11, 2022 FATE Sale $221,655 −12.6%−72.2%−73.5%
January 12, 2022January 10, 2022 FATE Sale $259,558 −5.0%−73.5%−74.7%
January 12, 2021January 8, 2021 FATE Sale $1,090,138 −35.4%−85.9%−82.3%
January 10, 2020January 8, 2020 FATE Sale $117,933 +48.2%+398.9%+414.0%
October 16, 2019October 15, 2019 FATE Sale $87,916 +63.3%+213.0%+199.7%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Valamehr Bahram traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.